Clinical trials aimed at increasing airway S-nitrosothiols, by inhibiting S-nitrosoglutathione reductase (GSNOR), are underway to enhance surface expression of cystic fibrosis transmembrane conductance regulator as treatment for cystic fibrosis. This evidence concerns the gene ADH5 and cystic fibrosis.